WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004096201) COMPOSITIONS FOR AFFECTING WEIGHT LOSS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/096201    International Application No.:    PCT/US2004/012393
Publication Date: 11.11.2004 International Filing Date: 21.04.2004
Chapter 2 Demand Filed:    23.02.2005    
IPC:
A61K 31/135 (2006.01), A61K 31/138 (2006.01), A61K 31/485 (2006.01)
Applicants: OREXIGEN THERAPEUTICS, INC. [US/US]; One Palmer Square, Suite 515, Princeton, NJ 08540 (US) (For All Designated States Except US).
WEBER, Eckard [US/US]; (US) (For US Only).
COWLEY, Michael, Alexander [AU/US]; (US) (For US Only)
Inventors: WEBER, Eckard; (US).
COWLEY, Michael, Alexander; (US)
Agent: MALLON, Joseph, J.; Knobbe Martens Olson & Bear LLP, 2040 Main Street, 14 Floor, Irvine, CA 92614 (US)
Priority Data:
60/466,838 29.04.2003 US
Title (EN) COMPOSITIONS FOR AFFECTING WEIGHT LOSS
(FR) COMPOSITIONS INFLUANT SUR LA PERTE DE POIDS
Abstract: front page image
(EN)Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance &agr;-MSH activity.
(FR)La présente invention concerne des compositions influant sur la perte de poids qui comprennent un premier composé et un second composé, le premier composé étant un antagoniste opioïde et le second composé entraînant un agonisme accru du récepteur de mélanocortine 3 (MC3-R) ou du récepteur de mélanocortine 4 (MC4-R) comparé à un état physiologique normal. Cette invention concerne aussi des techniques influant sur la perte de poids, augmentant la dépense d'énergie, augmentant la sensation de satiété d'une personne ou supprimant l'appétit d'une personne, qui consistent à identifier une personne qui peut tirer profit de ces techniques et à traiter cette personne de façon à antagoniser l'activité du récepteur d'opioïde et à renforcer l'activité a-MSH.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)